A team from the U.S. Broad Institute has published research findings in the Proceedings of the National Academy of Sciences, developing a new CRISPR-Cas9 regulation system called LF N-Acr/PA. This technology effectively reduces off-target effects in gene editing, providing a safer option for clinical applications of gene therapy.

The research team utilized components from anthrax toxin to construct a protein delivery system, achieving efficient intracellular delivery of anti-CRISPR proteins. Project leader Ronald Raines stated: "This is the first cell-penetrating anti-CRISPR protein system that can rapidly shut down Cas9 activity after editing is complete." Experimental data show that the system can increase gene editing specificity by 40%, with an action time of only a few minutes.

The technology has been submitted for patent application and is expected to improve treatment outcomes for genetic diseases such as sickle cell disease. Co-author Amit Choudhary noted: "This breakthrough lays the foundation for developing more precise and controllable gene therapies." The research team is further optimizing the system to expand its application scope in clinical treatments.